Page last updated: 2024-11-02

pioglitazone and Paraneoplastic Syndromes

pioglitazone has been researched along with Paraneoplastic Syndromes in 2 studies

Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.

Paraneoplastic Syndromes: In patients with neoplastic diseases a wide variety of clinical pictures which are indirect and usually remote effects produced by tumor cell metabolites or other products.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's0 (0.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Kalra, S1
Priya, G1
Bhattacharya, S1
Sahay, R1
Vogt, T1
Coras, B1
Hafner, C1
Landthaler, M1
Reichle, A1

Reviews

1 review available for pioglitazone and Paraneoplastic Syndromes

ArticleYear
Oncocrinology.
    JPMA. The Journal of the Pakistan Medical Association, 2020, Volume: 70, Issue:4

    Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Endocri

2020

Other Studies

1 other study available for pioglitazone and Paraneoplastic Syndromes

ArticleYear
Antiangiogenic therapy in metastatic prostate carcinoma complicated by cutaneous lupus erythematodes.
    The Lancet. Oncology, 2006, Volume: 7, Issue:8

    Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Capecit

2006